Una propuesta de descripción y clasificación | 12 OCT 15

Síndrome de superposición asma / EPOC

El asma y la EPOC, antes consideradas como enfermedades diferentes, son enfermedades heterogéneas y con frecuencia se superponen.
INDICE:  1.  | 2. 

1. Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2015) (http://www ginasthma .org/ local/ uploads/ files/ GINA_Report_2015_May19 .pdf).
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2015) (http://www .goldcopd .org/uploads/ users/ files/ GOLD_Report_2015_Apr2 .pdf).
3. Barker BL, Brightling CE. Phenotyping the heterogeneity of chronic obstructive pulmonary disease. Clin Sci (Lond) 2013; 124:  371-87.
4. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728-35.
5. de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middleaged and elderly people from the general population. PLoS One 2013; 8(5): e62985.
6. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92.
7. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109-14.
8. Tashkin DP. Variations in FEV1 decline over time in chronic obstructive pulmonary disease and its implications. Curr Opin Pulm Med 2013; 19: 116-24.
9. Postma DS, Kerstjens HAM. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: S187-92.
10. Grootendorst DC, Rabe KF. Mechanisms of bronchial hyperreactivity in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1: 77-87.
11. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 62-9.
12. Gunst SJ, Panettieri RA Jr. Point: alterations in airway smooth muscle phenotype do/do not cause airway hyperresponsiveness in asthma. J Appl Physiol (1985) 2012; 113: 837-9.
13. Prosperini G, Rajakulasingam K, Cacciola RR, et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol 2002; 110: 855-61.
14. Brown RH, Pearse DB, Pyrgos G, Liu MC, Togias A, Permutt S. The structural basis of airways hyperresponsiveness in asthma. J Appl Physiol (1985) 2006; 101:30-9.
15. Tracey M, Villar A, Dow L, Coggon D, Lampe FC, Holgate ST. The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1: a longitudinal study in the elderly. Am J Respir Crit Care Med 1995; 151: 656-62.
16. Kerstjens HAM, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413-9.
17. Rutgers SR, Ko.ter GH, van der Mark TW, Postma DS. Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5′-monophosphate in COPD. Am J Respir Crit Care Med 1998; 157: 880-6.
18. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
19. Rijcken B, Schouten JP, Xu X, Rosner B, Weiss ST. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med 1995; 151: 1377-82.
20. Tashkin DP, Altose MD, Bleecker ER, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992; 145: 301-10.
21. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151: 517-27.
22. van den Berge M, Vonk JM, Gosman M, et al. Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J 2012; 40: 1098-105.
23. Lan.as T, Kasahara DI, Gross JL, et al. Cholinergic hyperresponsiveness of peripheral lung parenchyma in chronic obstructive pulmonary disease. Respiration 2011; 82: 177-84.
24. Postma DS, de Vries K, Ko.ter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 1986; 134: 276-80.
25. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease: the Lung Health Study Research Group. Am J Respir Crit Care Med 1996; 153: 1802-11.
26. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356: 1313-7.
27. Vestbo J, Hansen EF. Airway hyperresponsiveness and COPD mortality. Thorax 2001; 56: Suppl 2: ii11-ii14.
28. Boros PW, Martusewicz-Boros MM. Reversibility of airway obstruction vs bronchodilatation: do we speak the same language? COPD 2012; 9: 213-5.
29. Postma DS, Reddel HK, ten Hacken NHT, van den Berge M. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin Chest Med 2014; 35: 143-56.
30. Bleecker ER, Emmett A, Crater G, Knobil K, Kalberg C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008; 21: 682-8.
31. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic Obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-51.
32. Verbanck S, Schuermans D, Noppen M, Van Muylem A, Paiva M, Vincken W. Evidence of acinar airway involvement in asthma. Am J Respir Crit Care Med 1999;159: 1545-50.
33. Verbanck S, Schuermans D, Van Muylem A, et al. Conductive and acinar lungzone contributions to ventilation inhomogeneity in COPD. Am J Respir Crit Care Med 1998; 157: 1573-7.
34. Sparrow D, O’Connor G, Weiss ST. The relation of airways responsiveness and atopy to the development of chronic obstructive lung disease. Epidemiol Rev 1988; 10: 29-47.
35. Fattahi F, ten Hacken NH, Löfdahl CG, et al. Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study. Respir Res 2013; 14: 10.
36. Jamieson DB, Matsui EC, Belli A, et al. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 187-92.
37. Sahn SA. Corticosteroids in chronic bronchitis and pulmonary emphysema. Chest 1978; 73: 389-96.
38. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-25.
39. Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2008; 14: 31-8.
40. Ravensberg AJ, Slats AM, van Wetering S, et al. CD8(+) T cells characterize early smoking-related airway pathology in patients with asthma. Respir Med 2013;107: 959-66.
41. Pignatti P, Ragnoli B, Radaeli A, Moscato G, Malerba M. Age-related increase of airway neutrophils in older healthy nonsmoking subjects. Rejuvenation Res 2011; 14: 365-70.
42. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19: 977-9.
43. Krug N, Hohlfeld JM, Kirsten AM, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015; 372: 1987-95.
44. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap: clinical relevance of genomic signatures of type 2 inflammation in COPD. Am J Respir Crit Care Med 2015; 191: 758-66.
45. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014; 44: 1697-700.
46. Siva R, Green RH, Brightling CE, et al.Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007; 29: 906-13.
47. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-73.
48. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010; 138: 682-92.
49. Orie NGM, Sluiter HJ, eds. Bronchitis. Assen, the Netherlands: Royal van Gorcum, 1962.

 

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024